PD168393 chemical structure
Chemical structureResearch use only
CAT. NO. DC9258Featured

PD168393

Pack Sizes & Prices

TotalUS$350
We match the best price and quality on market.
Product overview

Description & Application

PD168393 is an potent, cell-permeable, irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773, inactive against insulin, PDGFR, FGFR and PKC. target: EGFRIC 50: 0.7 nM [1](1) PD 168393 inhibite EGFr autophosphorylation in A431 human epidermoid carcinoma cells with >9-fold greater potency than PD 174265.[1](2) PD 168393 decrease the production of TNF-α and phosphrylation of ERK1/2 and p38 induced by LPS in cardiomyocytes.[2](3) PD168393 completely inhibits AKT and ERK phosphorylation at concentrations as low as 0.03 umol/L.[3](4) PD168393 could induce apoptosis and inhibit cell growth in ErbB2 positive lung and breast cancer cell lines.[3](5) PD168393 disrupted MEK1/p44/42 ERK signaling in HaCaT cells as determined by inhibition of phospho-p44/42 ERK. [4]

ParameterValue
Chemical NamePD168393
CAS No.194423-15-9
SynonymsPD 168393;N-[4-(3-bromoanilino)quinazolin-6-yl]prop-2-enamide;N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-propenamide;4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline;AC1L1IRY;AC1Q26CC;N-(4-(3-bromophenylamino)quinazoline-6-yl)acrylamide;N-[4-[(3-bromophenyl)-amino]-quinazolin-6-yl]-acrylamide;N-[4-[(3-Bromophenyl)amino]quinazolin-6-yl]-acrylamide;n-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide;nchembio866-comp2;PD-168393;SureCN2680536;N-(4-((3-Bromophenyl)amino)quinazolin-6-yl)acrylamide;2-Propenamide, N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-;PD168393;3R996Y9T0I;C17H13BrN4O;N-[4-(3-Bromo-phenylamino)-quinazolin-6-yl]-acrylamide;2-Propenamide, N-(4-((3-bromophenyl)amino)-6-quinazolinyl)-;N;4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline; N-[4-[(3-Bromophenyl)amino]-6-quinazolinyl]-2-propenamide;BDBM4567;s7039;SCHEMBL2680536;NCGC00386260-01;CHEMBL285063;PD 168393 [WHO-DD];AC-32813;N-(4-(3-Bromophenylamino)quinazolin-6-yl)acrylamide;AKOS027337569;PD168393?;N-{4-[(3-bromophenyl)amino]quinazolin-6-yl}prop-2-enamide;4-[(3-Bromophenyl)amino]-6-acrylamidoquinazoline;MFCD02179207;3968-03-4;NCGC00386260-02;CHEBI:131504;DTXSID80274444;HMS3652F18;SW218184-2;BCP07986;J-012594;DA-43376;PD168393, >=98% (HPLC);CCG-268278;EX-A808;NS00068483;HSCI1_000120;HTUBKQUPEREOGA-UHFFFAOYSA-N;CS-5723;4-anilinoquinazoline deriv. 2;BMC163482 Compound 1;SB19366;Q26998221;AS-67687;194423-15-9;F13662;HY-13896;N-[4-[(3-bromophenyl)amino]quinazolin-6-yl]acrylamide;DB07662;UNII-3R996Y9T0I;BRD-K17702546-001-03-2
FormulaC17H13BrN4O
M.Wt369.215322256088
SMILESBrC1=CC=CC(=C1)NC1=C2C=C(C=CC2=NC=N1)NC(C=C)=O
Purity>98%
Storage2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Biological Activity

PD168393 is an potent, cell-permeable, irreversible EGFR inhibitor with IC50 of 0.70 nM, irreversibly alkylate Cys-773, inactive against insulin, PDGFR, FGFR and PKC. target: EGFRIC 50: 0.7 nM [1](1) PD 168393 inhibite EGFr autophosphorylation in A431 human epidermoid carcinoma cells with >9-fold greater potency than PD 174265.[1](2) PD 168393 decrease the production of TNF-α and phosphrylation of ERK1/2 and p38 induced by LPS in cardiomyocytes.[2](3) PD168393 completely inhibits AKT and ERK phosphorylation at concentrations as low as 0.03 umol/L.[3](4) PD168393 could induce apoptosis and inhibit cell growth in ErbB2 positive lung and breast cancer cell lines.[3](5) PD168393 disrupted MEK1/p44/42 ERK signaling in HaCaT cells as determined by inhibition of phospho-p44/42 ERK. [4]

In Vitro

No in vitro data are provided in the current product source. Contact us for further information.

In Vivo

No in vivo data are provided in the current product source. Contact us for further information.

References & source

DC Chemicals original product information

Published experimental findings depend on the model and assay conditions. They do not guarantee equivalent performance in every application. For laboratory research use only.

Product documentation

View online datasheetRequest COA / MSDS

Refer to the certificate supplied with your lot for batch-specific release results.

Handling guide

2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Solution calculator

Related research products

WZ4002 chemical structureDC5090

WZ4002

WZ4002 is a mutant selective EGFR inhibitor with IC50s of 2, 8, 3 and 2 nM for EGFRL858R, EGFRL858R/T790M, EGFRE746_A750 and EGFRE746_A750/T790M, respectively.

View activity & prices
Rociletinib (CO-1686) chemical structureDC7106

Rociletinib (CO-1686)

Rociletinib (CO-1686) is an orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M, and the Ki values for EGFRL858R/T790M and EGFRWT are 21.5 nM and 303.3 nM, respectively.

View activity & prices
AZ5104 chemical structureDC8052

AZ5104

AZ-5104 is an active, demethylated metabolite of AZD 9291. AZ-5104 is an EGFR inhibitor with IC50s of 1, 6, 1, 25 and 7 nM for EGFRL858R/T790M, EGFRL858R, EGFRL861Q, EGFR and ErbB4, respectively.

View activity & prices

Cart

Request quotation